Related references
Note: Only part of the references are listed.Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance
Christina Charles-Schoeman et al.
ANNALS OF THE RHEUMATIC DISEASES (2023)
Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme
William J. Sandborn et al.
JOURNAL OF CROHNS & COLITIS (2023)
Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment
William J. Sandborn et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)
OP38 Tofacitinib for the treatment of Ulcerative Colitis: An integrated summary of safety data from the global OCTAVE and RIVETING clinical trials
W J Sandborn et al.
Journal of Crohns & Colitis (2022)
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
Steven R. Ytterberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
MAJOR ADVERSE CARDIOVASCULAR EVENTS, MALIGNANCIES AND VENOUS THROMBOEMBOLISM BY BASELINE CARDIOVASCULAR RISK: A POST HOC ANALYSIS OF ORAL SURVEILLANCE
M. H. Buch et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial
Severine Vermeire et al.
JOURNAL OF CROHNS & COLITIS (2021)
Moderate and High Disease Activity Predicts the Development of Carotid Plaque in Rheumatoid Arthritis Patients without Classic Cardiovascular Risk Factors: Six Years Follow-Up Study
Ivan Ferraz-Amaro et al.
JOURNAL OF CLINICAL MEDICINE (2021)
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC)
Frank L. J. Visseren et al.
EUROPEAN HEART JOURNAL (2021)
Thromboembolic and atherosclerotic cardiovascular events in inflammatory bowel disease: epidemiology, pathogenesis and clinical management
Jasmijn A. M. Sleutjes et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2021)
Disease activity influences the reclassification of rheumatoid arthritis into very high cardiovascular risk
Ivan Ferraz-Amaro et al.
ARTHRITIS RESEARCH & THERAPY (2021)
Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis
Bruce E. Sands et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Inflammatory Bowel Disease and Atherosclerotic Cardiovascular Disease JACC Review Topic of the Week
Miguel Cainzos-Achirica et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary
Donna K. Arnett et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017
Saeid Safiri et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials
William J. Sandborn et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Increased risk of acute arterial events in young patients and severely active IBD: a nationwide French cohort study
Julien Kirchgesner et al.
GUT (2018)
Clinical activity is an independent risk factor of ischemic heart and cerebrovascular arterial disease in patients with inflammatory bowel disease
Guillaume Le Gall et al.
PLOS ONE (2018)
EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update
R. Agca et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Risk of Cardiovascular Morbidity in Patients With Psoriatic Arthritis: A Meta-Analysis of Observational Studies
Ari Polachek et al.
ARTHRITIS CARE & RESEARCH (2017)
Cardiovascular disease in immune-mediated inflammatory diseases: A cross-sectional analysis of 6 cohorts
Benjamin Fernandez-Gutierrez et al.
MEDICINE (2017)
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Inflammatory Bowel Disease Is Associated With an Increased Risk of Hospitalization for Heart Failure A Danish Nationwide Cohort Study
Soren Lund Kristensen et al.
CIRCULATION-HEART FAILURE (2014)
Risk of Cerebrovascular Accidents and Ischemic Heart Disease in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
Siddharth Singh et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
Inflammation and Disease Activity are Associated with High Circulating Cardiac Markers in Rheumatoid Arthritis Independently of Traditional Cardiovascular Risk Factors
Jerome Avouac et al.
JOURNAL OF RHEUMATOLOGY (2014)
Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies
Juan Antonio Avina-Zubieta et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Epidemiology and Natural History of Inflammatory Bowel Diseases
Jacques Cosnes et al.
GASTROENTEROLOGY (2011)
Share Paper
